Bruker Corporation $BRKR is Grandeur Peak Global Advisors LLC's 7th Largest Position

Grandeur Peak Global Advisors LLC increased its stake in Bruker Corporation by 3.6% in Q2, making it their 7th largest position. Bruker's stock performance shows a market cap of $7.26 billion and a P/E ratio of 91.83. The company reported Q3 earnings of $0.45 per share, beating estimates. Bruker announced a quarterly dividend of $0.05 per share. Insider trading included sales by Directors John A. Ornell and Cynthia M. Friend. Analysts have recently updated their ratings on BRKR.

Grandeur Peak Global Advisors LLC lifted its position in Bruker Corporation (NASDAQ:BRKR - Free Report) by 3.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 743,794 shares of the medical research company's stock after buying an additional 25,692 shares during the quarter. Bruker makes up approximately 3.7% of Grandeur Peak Global Advisors LLC's portfolio, making the stock its 7th biggest holding. Grandeur Peak Global Advisors LLC owned approximately 0.49% of Bruker worth $30,644,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Nisa Investment Advisors LLC increased its holdings in Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company's stock worth $25,000 after acquiring an additional 487 shares during the period. Huntington National Bank grew its position in shares of Bruker by 750.0% during the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company's stock valued at $30,000 after purchasing an additional 645 shares in the last quarter. Spire Wealth Management purchased a new position in shares of Bruker during the 2nd quarter valued at $32,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Bruker by 1,354.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock worth $33,000 after purchasing an additional 745 shares during the period. Finally, Parallel Advisors LLC raised its position in shares of Bruker by 63.0% in the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company's stock worth $37,000 after buying an additional 347 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Stock Performance

NASDAQ:BRKR opened at $47.75 on Friday. The company has a market capitalization of $7.26 billion, a price-to-earnings ratio of 91.83, a PEG ratio of 5.31 and a beta of 1.26. The business has a 50 day moving average of $38.89 and a 200 day moving average of $37.62. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $64.64.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.33 by $0.12. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same period last year, the firm posted $0.60 earnings per share. The business's revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, sell-side analysts predict that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This represents a $0.20 annualized dividend and a yield of 0.4%. Bruker's payout ratio is currently -125.00%.

Insider Buying and Selling at Bruker

In other news, Director John A. Ornell sold 6,233 shares of the business's stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the sale, the director owned 35,212 shares of the company's stock, valued at approximately $1,373,268. The trade was a 15.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the sale, the director owned 18,016 shares of the company's stock, valued at $581,016. This represents a 16.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 27.30% of the company's stock.

Analyst Ratings Changes

BRKR has been the subject of several recent analyst reports. Rothschild Redb upgraded Bruker to a "strong-buy" rating in a research report on Thursday, November 20th. Rothschild & Co Redburn started coverage on Bruker in a research report on Thursday, November 20th. They set a "buy" rating and a $60.00 price target for the company. Wells Fargo & Company cut their price objective on Bruker from $50.00 to $48.00 and set an "overweight" rating for the company in a report on Wednesday, November 5th. Cowen restated a "hold" rating on shares of Bruker in a research report on Tuesday, November 4th. Finally, Barclays lifted their target price on shares of Bruker from $40.00 to $45.00 and gave the company an "overweight" rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $50.25.

Read Our Latest Stock Analysis on Bruker

About Bruker

(Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Should You Invest $1,000 in Bruker Right Now?

Before you consider Bruker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.

While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here